Exenatide vs Tirzepatide
Side-by-side comparison of Exenatide and Tirzepatide: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
Exenatide
Tirzepatide
Exenatide
Exenatide (Byetta, Bydureon) is a synthetic exendin-4 GLP-1 receptor agonist, FDA-approved for type 2 diabetes, that lowers blood glucose and curbs appetite. Available as a twice-daily immediate-release and a once-weekly…
No vendor price on file.
Full Exenatide profileTirzepatide
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid…
Lowest listed price: $49.00 across 14 listings
Full Tirzepatide profileSide-by-side comparison
| Attribute | Exenatide | Tirzepatide |
|---|---|---|
| Category | Weight Loss | Metabolic & Weight Loss |
| Research Stage | FDA-approved | FDA Approved |
| Mechanism of Action | Exenatide is a synthetic form of exendin-4, a 39-amino-acid peptide first isolated from the saliva of the Gila monster (Heloderma suspectum). It shares about 53 percent of its sequence with human GLP-1 but, unlike native GLP-1, resists breakdown by the DPP-4… | Dual GLP-1 and GIP Receptor Agonism Tirzepatide simultaneously activates two incretin receptors: the GLP-1 receptor and the GIP receptor. While the GLP-1 receptor component provides the well-established effects of GLP-1 agonism (glucose-dependent insulin… |
| Half-Life | Immediate-release (Byetta): terminal half-life about 2.4 hours, cleared mainly by the kidneys. Extended-release (Bydureon): the same peptide is released slowly from biodegradable microspheres over roughly 10 weeks, reaching steady-state plasma levels by about 6 to 7 weeks. | ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification |
| Typical Dose Range | 5 to 10 mcg twice daily (Byetta, immediate-release) or 2000 mcg (2 mg) once weekly (Bydureon, extended-release) | 2500 mcg (2.5 mg) starting dose, titrated every 4 weeks through 5000, 7500, 10000, 12500, to 15000 mcg (15 mg) maximum weekly dose |
| Dosing Frequency | Twice daily before meals (immediate-release) or once weekly (extended-release) | Once weekly subcutaneous injection |
| Administration | — | Subcutaneous (weekly) |
| Side Effects | Gastrointestinal effects are by far the most common: nausea (reported in roughly 40 to 57 percent of patients on the twice-daily form, usually worst early and fading over weeks), vomiting, diarrhea, constipation, and dyspepsia. Reduced appetite is expected.… | Mild to moderate nausea (especially at initiation), headache, fatigue, constipation or diarrhea, abdominal distension. Injection site reactions. Rare: hypoglycemia, increased heart rate, pancreatitis. |
| Molecular Weight | 4186.6 g/mol (molecular formula C184H282N50O60S) | 4813.5 Da |
| Common Vial Sizes | — | 5mg, 10mg, 15mg |
Price History
3 data points- BM
- Half Nattys
- Ion Peptide
Exenatide: potential benefits
- Meaningful glycemic control in type 2 diabetes, with HbA1c reductions of roughly 1.0 to 1.9 percent in randomized trials
- Weight reduction of about 2 to 3 kg in diabetic trials, driven mainly by reduced appetite and slower gastric emptying
- Low intrinsic hypoglycemia risk because insulin release is glucose-dependent (risk rises when combined with sulfonylureas or insulin)
- Strong control of post-meal glucose spikes
- Cardiovascular safety shown in a large outcomes trial, with no increase in major cardiac events
- Can be added to basal insulin to improve control while offsetting insulin-related weight gain
- Once-weekly extended-release option (Bydureon) reduces injection burden versus twice-daily dosing
- In people without diabetes the appetite effect is real, but standalone weight loss has been modest and less consistent than newer agents such as [semaglutide](/compound/semaglutide) or [tirzepatide](/compound/tirzepatide)
Tirzepatide: potential benefits
- Mean body weight reduction of 20.9% at 72 weeks on 15 mg for everyone randomized (treatment-regimen estimand), 22.5% in the efficacy estimand (SURMOUNT-1, PMID: 35658024)
- 36.2% of participants achieved greater than or equal to 25% body weight loss (PMID: 35658024)
- Significant HbA1c reduction in type 2 diabetes (up to 2.4% at 40 weeks in the SURPASS-5 add-on-to-insulin trial) (PMID: 35133415)
- Potentially superior lean mass preservation versus GLP-1-only agents due to GIP component
- Dual incretin mechanism providing complementary metabolic benefits
- Improved lipid profiles including triglycerides, LDL cholesterol, and HDL cholesterol
- Reduction in waist circumference and markers of visceral adiposity (PMID: 37840095)
Frequently asked
What's the difference between Exenatide and Tirzepatide?
Exenatide is a weight loss that exenatide is a synthetic form of exendin-4, a 39-amino-acid peptide first isolated from the saliva of the gila monster (heloderma suspectum). it shares about 53 percent of its…. Tirzepatide is a metabolic & weight loss that dual glp-1 and gip receptor agonism tirzepatide simultaneously activates two incretin receptors: the glp-1 receptor and the gip receptor. while the glp-1 receptor component…. The two differ in mechanism, half-life (Immediate-release (Byetta): terminal half-life about 2.4 hours, cleared mainly by the kidneys. Extended-release (Bydureon): the same peptide is released slowly from biodegradable microspheres over roughly 10 weeks, reaching steady-state plasma levels by about 6 to 7 weeks. vs ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification), and typical dose range.
Which has the longer half-life, Exenatide or Tirzepatide?
Exenatide has a half-life of Immediate-release (Byetta): terminal half-life about 2.4 hours, cleared mainly by the kidneys. Extended-release (Bydureon): the same peptide is released slowly from biodegradable microspheres over roughly 10 weeks, reaching steady-state plasma levels by about 6 to 7 weeks.. Tirzepatide has a half-life of ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Can you stack Exenatide and Tirzepatide?
Stacking depends on mechanism overlap, safety profile, and goals. Exenatide and Tirzepatide should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy Exenatide or Tirzepatide
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.